Remarkably, the combination of anti-PDL1 and B10G5 resulted in a further significant inhibition of tumor growth and improved survival as compared to monotherapy of B10G5, suggesting a cooperative therapeutic effect of targeting sMIC and PD1/PDL1 blockade. Here, PDCD1 is linked to neoplasm.